Zobrazeno 1 - 10
of 97
pro vyhledávání: '"Yi Jen Liao"'
Publikováno v:
Molecular Therapy: Oncolytics, Vol 17, Iss , Pp 571-585 (2020)
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with a 5-year survival rate of 9%. Major obstacles to successful treatment of pancreatic cancer are the immunosuppressive tumor microenvironment (TME) and antigenic complexity or hetero
Externí odkaz:
https://doaj.org/article/3eb61f68d3cd4091bfbc24084b804085
Publikováno v:
Life, Vol 10, Iss 10, p 246 (2020)
To investigate the association of immunosenescence with aged-related morbidity in the elderly, a clinical study was conducted to analyze and compare the alterations in peripheral blood (PB) T-cell subsets among young healthy (YH) controls, elderly he
Externí odkaz:
https://doaj.org/article/b29382beddaa4fe1ad73a19a38b98bff
Publikováno v:
Ecotoxicology and Environmental Safety, Vol 273, Iss , Pp 116161- (2024)
Di(2-ethylhexyl) phthalate (DEHP) is a worldwide common plasticizer. Nevertheless, DEHP is easily leached out to the environment due to the lack of covalent bonds with plastic. High dose of DEHP exposure is often observed in hemodialysis patients bec
Externí odkaz:
https://doaj.org/article/9c5ae673a6754ce5b9e02decea97f485
Autor:
Yi-Jen Liao, Chun-Ya Lee, Yuh-Ching Twu, Fat-Moon Suk, Tzu-Chieh Lai, Ya-Ching Chang, Yi-Cheng Lai, Jing-Wei Yuan, Hong-Ming Jhuang, Huei-Ruei Jian, Li-Chia Huang, Kuang-Po Chen, Ming-Hua Hsu
Publikováno v:
Bioengineering, Vol 10, Iss 9, p 1075 (2023)
The increased proliferation and activation of hepatic stellate cells (HSCs) are associated with liver fibrosis development. To date, there are no FDA-approved drugs for the treatment of liver cirrhosis. Augmentation of HSCs apoptosis is one of the re
Externí odkaz:
https://doaj.org/article/bed4ef76c68a40bd989fc335a61adef8
Publikováno v:
Molecules, Vol 27, Iss 22, p 8015 (2022)
Primary liver cancer is the fifth leading death of cancers in men, and hepatocellular carcinoma (HCC) accounts for approximately 90% of all primary liver cancer cases. Sorafenib is a first-line drug for advanced-stage HCC patients. Sorafenib is a mul
Externí odkaz:
https://doaj.org/article/58d842b9d31641f2aea0db9d1e82d3fa
Autor:
Chia-Hung Yen, Chih-Chung Lai, Chen-Chung Liao, Sheng-Fan Wang, Yi-Jen Liao, Chien-Yi Tung, Jung-Hsien Hung, Shiu-Feng Huang, Yi-Ming Arthur Chen
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-14 (2017)
Abstract Sarcomatoid hepatocellular carcinoma (SHC) is a rare type of HCC with significantly poorer survival than ordinary HCC. Little is known about the mechanism associated with SHC and its biomarkers and therapy. Here, we established a mouse liver
Externí odkaz:
https://doaj.org/article/7fc683ec0bfb40a7af09f8ebb59e314f
Publikováno v:
The Journal of Nutritional Biochemistry. 115:109267
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8190476d75a3b32de7013e3828d99651
https://doi.org/10.1016/j.jnutbio.2023.109267
https://doi.org/10.1016/j.jnutbio.2023.109267
Publikováno v:
Glycobiology. 31:624-635
Cell surface glycosylation has been known as an important modification process that can be targeted and manipulated by malignant cells to escape from host immunosurveillance. We previously showed that the blood group branched I antigen on the leukemi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf02b58886969f6d43b6d56a1d33239e
https://doi.org/10.1093/glycob/cwaa117
https://doi.org/10.1093/glycob/cwaa117
Publikováno v:
Molecular Therapy: Oncolytics, Vol 17, Iss, Pp 571-585 (2020)
Molecular Therapy Oncolytics
Molecular Therapy Oncolytics
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with a 5-year survival rate of 9%. Major obstacles to successful treatment of pancreatic cancer are the immunosuppressive tumor microenvironment (TME) and antigenic complexity or hetero
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::464b9face6d41d3f627b71117a3d9e72
https://doi.org/10.1016/j.omto.2020.05.009
https://doi.org/10.1016/j.omto.2020.05.009
Autor:
Fat Moon Suk, Yuan Hsi Wang, Chien Ying Wu, Tzu Lang Chen, Chiao Fan Liu, Wan Chun Chiu, Yi Jen Liao
Publikováno v:
International Journal of Molecular Sciences
Volume 22
Issue 16
International Journal of Molecular Sciences, Vol 22, Iss 8567, p 8567 (2021)
Volume 22
Issue 16
International Journal of Molecular Sciences, Vol 22, Iss 8567, p 8567 (2021)
Hepatocellular carcinoma (HCC) is the most common primary malignant tumor in the world. Sorafenib is the first-line drug for patients with advanced HCC. However, long-term treatment with sorafenib often results in reduced sensitivity of tumor cells t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7850ae806dad4a337ed5eb35b4795429